University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.
Galanina N, Smith SM, Liao C, Petrich A, Libao B, Gartenhaus R, Westin JR, Cohen KS, Knost JA, Stadler WM, Doyle A, Karrison T, Gordon LI, Evens AM.
Galanina N, et al. Among authors: knost ja.
Br J Haematol. 2018 Apr;181(2):264-267. doi: 10.1111/bjh.14544. Epub 2017 Apr 17.
Br J Haematol. 2018.
PMID: 28419407
Free PMC article.
Clinical Trial.
No abstract available.